ePrints

Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives

Lookup NU author(s): Dr Nisreen Al-NamnamORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

The remodeling process results from the action of the tissue-forming osteoblasts and the tissue-resorbing osteoclasts which work together in certain cell units called basic multicellular units (BMUs). The local regulation of the bone cell function includes the receptor activator of nuclear factor κB ligand (RANKL)/ receptor activator of nuclear factor κB (RANK) / Osteoprotegerin (OPG) system. These molecules are key factors linking bone formation to resorption during the bone remodeling process. The OPG/RANKL/RANK system has a role in the pathogenesis of bone loss by modulating RANK-induced osteoclastogenesis. This role has provided the rationale for drug development that treats bone diseases. Systemic OPG therapy was used for bone disease treatment parenteral. According to our knowledge that got from researches, there is no study has been done to explore the use of the local delivery system of OPG in bone resorption treatment. This approach may have similar osteogenic potential in bone defects that might be capable of treatment bone loss.

Publication metadata

Author(s): Jayash SN, Al-Namnam NM, Shaghayegh G

Publication type: Article

Publication status: Published

Journal: Biointerface Research in Applied Chemistry

Year: 2021

Volume: 10

Issue: 2

Pages: 5193-5200

Online publication date: 03/02/2020

Acceptance date: 23/02/2020

Date deposited: 26/07/2021

ISSN (electronic): 2069-5837

Publisher: Biointerface Research in Applied Chemistry

URL: https://doi.org/10.33263/BRIAC102.193200

DOI: 10.33263/BRIAC102.193200

Altmetrics

Share